Botulinum toxin A (BoNT-A) is considered a safe and effective therapy for children with
cerebral palsy (CP), especially in the hands of experienced injectors and for the majority of …

An interdisciplinary European group of clinical experts in the field of movement disorders
and experienced Botulinum toxin users has updated the consensus for the use of Botulinum …

Botulinum neurotoxin type‐A (BoNT‐A) has been used in association with other
interventions in the management of spasticity in children with cerebral palsy (CP) for almost …

During the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used
medical intervention in children with cerebral palsy. In this review we consider the gaps in …

The intramuscular application of botulinum toxin type A (BoNT/A) has emerged to be an
established treatment option to reduce muscular hyperactivity due to spasticity in children …

This retrospective study aimed to examine the safety of botulinum toxin A (BoNT-A)
treatment in a paediatric multidisciplinary cerebral palsy clinic. In a sample of 454 patients …

Objectives In the last 2 decades, BTX-A is increasingly being used in the management of
spasticity in children with Cerebral Palsy (CP) and there is no doubt about its effect on range …

At the University Hospital of Pellenberg (Belgium), more than 1000 patients have been
treated with Botulinum toxin type A (BTX-A) over the last decade. Ten percent of these …

The long‐term effects of botulinum toxin A (BoNT‐A) treatment in children with cerebral
palsy (CP) are still elusive. We studied a prospective clinical cohort of 94 children with …

Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-
A) in the treatment of children with cerebral palsy (CP), with a special focus on the lower …